News
Eli Lilly, Novo Nordisk and Zepbound
Digest more
Eli Lilly, the drugmaker with two weight-loss bestsellers, just got its first dose of healthy ... Novo stock has been falling for much of the past year due to increased competition and ...
Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...
Eli Lilly's stock boomed April 17 after announcing a new experimental pill that caused nearly 8% weight loss at certain dosages and lowered blood sugar in patients during a clinical trial.
Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...
Eli Lilly shares jumped ... s clinical trial registry, Lilly’s primary obesity trial is not expected to conclude until at least July. An oral version of weight loss drugs could pose a threat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback